MARKET

CYTOF

CYTOF

Altamira Therapeutics Ltd
OTCMQB
0.065
0.000
0.00%
Closed 09:44 07/11 EDT
OPEN
0.065
PREV CLOSE
0.065
HIGH
0.065
LOW
0.065
VOLUME
1.00K
TURNOVER
65
52 WEEK HIGH
1.530
52 WEEK LOW
0.050
MARKET CAP
303.04K
P/E (TTM)
-0.0218
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CYTOF last week (0630-0704)?
Weekly Report · 5d ago
Weekly Report: what happened at CYTOF last week (0623-0627)?
Weekly Report · 06/30 12:16
Weekly Report: what happened at CYTOF last week (0616-0620)?
Weekly Report · 06/23 12:05
Weekly Report: what happened at CYTOF last week (0609-0613)?
Weekly Report · 06/16 12:15
Altamira Therapeutics Announces AGM Results and Board Elections
TipRanks · 06/11 20:48
Weekly Report: what happened at CYTOF last week (0602-0606)?
Weekly Report · 06/09 12:17
Weekly Report: what happened at CYTOF last week (0526-0530)?
Weekly Report · 06/02 12:30
ALTAMIRA THERAPEUTICS ANNOUNCES COLLABORATION ON CIRCULAR RNA DELIVERY
Reuters · 05/27 13:00
More
About CYTOF
Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore/ SemaPhore platforms). The Company has over two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. Its delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. AM-401, the drug product is based on its OligoPhore technology.

Webull offers Altamira Therapeutics Ltd stock information, including OTCMQB: CYTOF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTOF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYTOF stock methods without spending real money on the virtual paper trading platform.